key: cord-1032103-uykdmegc authors: Salimi, Vahid; Viegas, Mariana; Trento, Alfonsina; Agoti, Charles N.; Anderson, Larry J.; Avadhanula, Vasanthi; Bahl, Justin; Bont, Louis; Brister, J. Rodney; Cane, Patricia A.; Galiano, Mónica; Graham, Barney S.; Hatcher, Eneida L.; Hellferscee, Orienka; Henke, David M.; Hirve, Siddhivinayak; Jackson, Sandra; Keyaerts, Els; Kragten-Tabatabaie, Leyla; Lindstrom, Stephen; Nauwelaers, Inne; Nokes, D. James; Openshaw, Peter J.; Peret, Teresa C.; Piedra, Pedro A.; Ramaekers, Kaat; Rector, Annabel; Trovão, Nídia Sequeira; von Gottberg, Anne; Zambon, Maria; Zhang, Wenqing; Williams, Thomas C.; Barr, Ian G.; Buchholz, Ursula J. title: Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level date: 2021-06-03 journal: Emerg Infect Dis DOI: 10.3201/eid2706.204608 sha: ef326c3530afd11a0d9683ed3e4f01ce187945cf doc_id: 1032103 cord_uid: uykdmegc Human respiratory syncytial virus (HRSV) is the leading viral cause of serious pediatric respiratory disease, and lifelong reinfections are common. Its 2 major subgroups, A and B, exhibit some antigenic variability, enabling HRSV to circulate annually. Globally, research has increased the number of HRSV genomic sequences available. To ensure accurate molecular epidemiology analyses, we propose a uniform nomenclature for HRSV-positive samples and isolates, and HRSV sequences, namely: HRSV/subgroup identifier/geographic identifier/unique sequence identifier/year of sampling. We also propose a template for submitting associated metadata. Universal nomenclature would help researchers retrieve and analyze sequence data to better understand the evolution of this virus. H uman respiratory syncytial virus (HRSV) is the leading cause of severe respiratory illness in children <5 years of age and is associated with substantial illness from lower respiratory tract infections in industrialized countries and substantial illness and death in low-and middle-income countries (1) (2) (3) (4) (5) . HRSV also causes severe disease among elderly and high-risk adults (6) . In 2016, HRSV was reclassifi ed by the International Committee on Virus Taxonomy (ICTV) into a new family, Pneumoviridae, genus, Orthopneumovirus, and species, Human orthopneumovirus. (7) . The wider availability of viral sequencing technologies has increased submissions of HRSV sequences to databases ( Figure 1 ), a trend we anticipate will continue. Human respiratory syncytial virus (HRSV) is the leading viral cause of serious pediatric respiratory disease, and lifelong reinfections are common. Its 2 major subgroups, A and B, exhibit some antigenic variability, enabling HRSV to circulate annually. Globally, research has increased the number of HRSV genomic sequences available. To ensure accurate molecular epidemiology analyses, we propose a uniform nomenclature for HRSV-positive samples and isolates, and HRSV sequences, namely: HRSV/subgroup identifi er/geographic identifi er/unique sequence identifi er/year of sampling. We also propose a template for submitting associated metadata. Universal nomenclature would help researchers retrieve and analyze sequence data to better understand the evolution of this virus. Although ICTV provides nomenclature standards for virus taxa, there is currently no standardized format for HRSV nomenclature below the species level. Given the current interest in both HRSV and database submissions, a standard nomenclature is needed to simplify studies of the genomic diversity of HRSV strains and variants below the species level. ICTV's taxonomic reassignment provides us a timely opportunity to propose a universal naming convention for HRSV strains, sequences, and isolates, including a framework for database submissions that are rich in contextual information and associated metadata. Several large laboratory HRSV surveillance and epidemiology studies are currently in progress. These studies include the World Health Organization's Global Respiratory Syncytial Virus (WHO RSV) Surveillance Project (https://www.who.int/influenza/rsv), which conducts large-scale testing for HRSV and extensive sequencing of HRSV-positive clinical specimens from >20 countries worldwide. Focused molecular analyses have helped elucidate HRSV household (8) and local (9) transmission dynamics and may guide development of strategies for the control of HRSV transmission. For example, molecular analysis showed that HRSV in healthcare facilities can be acquired from sources within the facility or introduced from the community (10, 11) . In temperate climates, annual HRSV epidemics usually occur in winter months; it remains to be seen how social distancing measures and nonpharmaceutical interventions due to the current coronavirus disease (COVID-19) pandemic will affect global HRSV circulation patterns. One of the 2 major genetic and antigenic HRSV subgroups, A or B, usually predominates in alternating years, but both subgroups can also co-circulate in the same season. Early research has shown that subgroup A HRSV is associated with slightly greater clinical severity than subgroup B (12) . Disease severity has been correlated with specific strains, genotypes, or clades, but to date, no consistent association has been established between strains (13-15), genotypes, or clades (16) (17) (18) (19) and virulence. Thus, a possible role of different HRSV strains in disease severity remains to be elucidated. The lack of standard nomenclature and the scarcity of rich metadata in databases currently limit and complicate such studies. Reliable and concise nomenclature systems below the species level are available for measles virus, influenza virus, rotavirus, filovirus isolates (20) (21) (22) (23) , and many other human viral pathogens. A similar nomenclature system tailored to HRSV and its pathology would support the requirements of researchers and the public health community by minimizing information errors when handling, storing, and shipping HRSV samples and when submitting, searching, and displaying sequencing data and associated metadata. Moreover, consistent nomenclature would improve the ability of researchers to pool and analyze data and associated information from different sources. To fill this need, an international group of researchers, in conjunction with the WHO RSV Global Surveillance Project, proposes a concise nomenclature system for HRSV below the species level. Table) , except for the M2 mRNA, which contains 2 overlapping ORFs. The 11 HRSV proteins are 2 nonstructural proteins (NS1 and NS2), nucleoprotein (N), phosphoprotein (P), matrix protein (M), small hydrophobic envelope protein (SH), attachment glycoprotein (G), fusion glycoprotein (F), the transcription processivity factor (M2-1), RNA regulatory factor (M2-2), and large RNA polymerase protein (L) (Table) (24, 25) . The F glycoprotein is the major viral neutralization and protective antigen, followed by the G glycoprotein (26) . HRSV subgroups A and B exhibit genomewide nucleotide and amino acid divergence (Figure 2 , panel A) (25, 27) . The reference sequences for the 2 subgroups are derived from strains HRSV A2 (28-31; GenBank accession number M74568.1; RefSeq accession number NC_038235) and HRSV B1 (32; Gen-Bank accession number AF013254.1; RefSeq accession number NC_001781.1; Figure 2 , panel B). F glycoprotein sequences between the 2 subgroups are well conserved (89% aa identity), whereas the G glycoproteins are the most divergent (53% aa identity between the subgroups) among the HRSV proteins ( Figure 2 , panel A) and undergo continuous molecular evolution. The ectodomain of the G glycoproteins of both subgroups contains a conserved central domain, representing an important antigenic site, flanked by 2 hypervariable domains (33) . Except for the central conserved region, the antigenic cross-reactivity between G glycoproteins of the 2 subgroups is low (26) . Because the G ORF exhibits the greatest degree of genetic variability between isolates, it is most commonly used for studies on the molecular evolution of HRSV. The genetic variability of HRSV strains over time has been commonly determined by sequencing the distal C-terminal third of the G ORF, which includes the second hypervariable domain. The variability in the G ORF is characterized by a high rate of nonsynonymous nucleotide changes, suggesting that evolution may be driven by immune pressure, even though this factor may be partially antibody independent (34) . It is likely that variability in the G protein contributes to the capacity of HRSV to cause yearly outbreaks in the community (35) (36) (37) . The nomenclature proposal outlined herein will be useful for the sequence analyses required to follow the molecular evolution of HRSV. In a parallel effort, several research groups are working together on a genotyping proposal to provide a consensus on uniform genotype designations (38, 39) . As virus evolution continues, we expect new genotypes to emerge and older genotypes to become extinct. HRSV genotyping designations will need to capture present molecular evolutionary status and be adaptable to changes and will need to be reevaluated periodically by a global consortium. For molecular epidemiology studies, a concise standard for short identifiers of specific HRSV sequences, suitable for the short definition lines that give context to a sample and its derived sequence, would be useful. Ideally, concise standardized identifiers should convey key information about each individual sequence in an alignment or phylogram, including source, date, and type, if known. Here, we aim to define this type of common naming convention for HRSV samples and isolates. We also propose the use using standard names and appropriate annotations for HRSV genes, provide examples to guide the annotation of sequence data during the sequence submission process, and suggest how to submit metadata associated with the source materials of HRSV sequences. Our nomenclature proposal prioritizes a short, concise definition line that will be easy to use in the laboratory, easily readable, and be a uniform system for HRSV in public databases. Additional host, virus, location or temporal information if desired could be submitted in metadata fields, which would allow researchers, epidemiologists, and database users to apply specific metadata filters, as needed for data retrieval and specific applications, analyses, or for displaying designations, such as in dendrograms. To support efficient data analysis, uniform designations must be used at the database submission stage. What is the most pertinent host data will depend on the interests and objectives of individual study groups. For example, when studying HRSV in a pediatric setting, prematurity may be of interest, but when studying HRSV in an adult setting, researchers may be more interested in whether participants are immunocompromised. We suggest information that could be included in metadata fields for HRSV: We highly recommend that the exact date of specimen collection (DD-Mon-YYYY format; e.g., 17-Feb-2002) be used; if exact date is not known, at least the month and year should be indicated (Mon-YYYY format). Associated with the International RSV Society, a special interest group of the International Society for Influenza and other respiratory viruses https://www. isirv.org/site/index.php/special-interest-groups/ international-respiratory-syncytial-virus-society. Protected personally identifiable health information will be excluded from metadata submissions. • If >6 months of age, birthweight and gestational age at birth. • Significant pediatric co-morbidities, including prematurity, congenital cardiac disease, and broncho-pulmonary dysplasia (BPD). • Twin? (Y/N) • Exposed to specific HRSV therapeutic, vaccine, antibody, or antiviral? (Y/N) • Viral or bacterial co-infections, if known; pathogen species should be spelled out. • Adult underlying conditions, such as chronic obstructive pulmonary disease (COPD) or asthma, or altered immune status (e.g., immunocompromised, bone marrow transplant recipient). • Disease outcomes. Five grades are distinguished: ¡ No medical care. ¡ Outpatient or emergency room. ¡ Hospital admission. ¡ ICU admission. ¡ Death. For NCBI submissions, data can be entered through the web interface, or uploaded as tab-delimited text files. Sequences can be uploaded in FASTA format (https://blast.ncbi.nlm.nih.gov; Appendix, https://wwwnc.cdc.gov/EID/article/27/6/20-4608-App1.pdf), with associated metadata provided in a plain text, tab-delimited, source modifier table (Appendix Table 1 ) and gene or protein annotations provided in a plain text, tab-delimited, 5-column feature table (Appendix Table 2 ). Molecular surveillance has revealed that multiple HRSV genotypes circulate simultaneously in communities. Circulating genotypes often vary between communities, and circulation patterns within a community can change from year to year. Extended monitoring of circulating viruses is necessary to better understand transmission and molecular evolution (42) . As HRSV vaccine candidates and antivirals are being developed, molecular epidemiology studies may reveal potential effects of prevention strategies on viral evolution and possible antibody-escape variants. Timely sharing of HRSV data worldwide through the use of public databases is essential. We propose that sequence data be uploaded to publicly accessible databases, such as NCBI (31) . Although NCBI is the most complete repository for HRSV sequence information, studies may require that sequences first be submitted to other databases, such as GISAID (https://www.gisaid.org). Public access will provide useful availability for investigators to submit, query, and analyze HRSV sequence data, enabling the evolutionary analysis of sequence diversity within or between HRSV genotypes. The utility of public access has been clearly demonstrated with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the critical role that genetic sequence analysis has played. Notably, a nomenclature model for SARS-CoV-2 similar to what we have proposed for HRSV has been adopted, although some differences remain between databases (e.g., NCBI, SARS-CoV-2/human/USA/ COVID20-1096/2020; GISAID, hCoV-19/Australia/ VIC12/2020). When an HRSV vaccine becomes available, high-quality, geographically representative, country-specific data on circulating strains and rich datasets of well-curated, standardized, and parsable data will be required to monitor and trace possible evolutionary changes in response to vaccine-induced selective pressure (43, 44) . This proposal will profit from strong support by members of the International RSV Society, a special interest group of the International Society for Influenza and other Respiratory Virus Diseases (https://isirv.org), members of the WHO Global RSV Surveillance Project, and the HRSV research community. RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet Prevalence of human respiratory syncytial virus circulating in Iran Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multicountry case-control study Respiratory syncytial virus infection in elderly and high-risk adults Ictv Report Consortium. ICTV virus taxonomy profile: Pneumoviridae Genomic analysis of respiratory syncytial virus infections in households and utility in inferring who infects the infant Molecular characterization of respiratory syncytial viruses circulating in a paediatric cohort in Amman Molecular characterization of a respiratory syncytial virus outbreak in a hematology unit in Heidelberg The clinical and phylogenetic investigation for a nosocomial outbreak of respiratory syncytial virus infection in an adult hemato-oncology unit Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children Molecular characterization of the glycoprotein and fusion protein in human respiratory syncytial virus subgroup A: Emergence of ON-1 genotype in Iran High epidemic burden of RSV disease coinciding with genetic alterations causing amino acid substitutions in the RSV G-protein during the 2016/2017 season in The Netherlands Differential interferon gene expression in bronchiolitis caused by respiratory syncytial virus-A genotype ON1 Respiratory syncytial virus: the influence of serotype and genotype variability on clinical course of infection Clinical profiles of respiratory syncytial virus subtypes A and B among children hospitalized with bronchiolitis Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons Correlation between respiratory syncytial virus genotype and severity of illness Measles virus nomenclature update Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG) Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease Respiratory syncytial virus and metapneumovirus Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years Two distinct subtypes of human respiratory syncytial virus Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus Nucleotide sequences of the 3′ leader and 5′ trailer regions of human respiratory syncytial virus genomic RNA Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation Database resources of the National Center for Biotechnology Information Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants Conservation of G-protein epitopes in respiratory syncytial virus (group A) despite broad genetic diversity: is antibody selection involved in virus evolution? Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses Analysis of respiratory syncytial virus strain variation in successive epidemics in one city Toward unified molecular surveillance of RSV: A proposal for genotype definition. Influenza Other Respir Viruses Towards a unified classification for human respiratory syncytial virus genotypes The GenBank Submissions Handbook. Bethesda (MD): National Center for Biotechnology Information Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene Vaccine development for respiratory syncytial virus Respiratory Syncytial Virus Network (ReSViNET) Foundation. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates Address for correspondence: Ian Barr, Peter Doherty Institute for Infection & Immunity National Institutes of Health, 50 South Dr, 50/6503 This manuscript is dedicated to the memory of Jose A. Melero, a superb scientist and leader in the HRSV field and a wonderful and generous friend to us all.